Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 4/2012

01.12.2012 | short review

Significant heterogeneity between centers during early evaluation of the first Turkish multi-centric study in the treatment of childhood acute lymphoblastic leukemia

verfasst von: Lebriz Yüksel-Soycan

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

The key of success in the treatment of pediatric acute lymphoblastic leukemia (ALL) has been the conduct of multi-centric clinical studies. With the aim of repeating the favorable results reported by the BFM group and reaching uniformity in diagnosis and treatment, the first Turkish multi-centric study in the treatment of pediatric ALL, BFM-TR ALL 2000, was opened to patient accrual in January 2000.

Methods

A total of 2,685 patients 0–18 years old from 32 different centers were registered until 31 December 2010. The treatment was a modified BFM-ALL 95 protocol. There was a common database, but no central morphological review.

Results

The median age was 5.2 years and the male:female ratio was 1.4. The median white blood cell (WBC) count was 13,900/μl and 14 % of the patients had a WBC count > 100,000/μl. Initial central nervous system involvement was seen in 3.5 % (range 0–13 %) of the patients and 18 % (4–13 %) had T-ALL. During induction, 0.5 % of the patients abandoned treatment and 2.5 % toxic deaths (range 0–9.2 %) resulted in 96.4 % remission rate. Non-relapse related mortality (8.7 %, range 0–15.9 %) was an important cause of failure early in remission and 3 % of the patients dropped-out before treatment was completed. Poor prednisone response rate was 14.5 % (range 4.3–27.2 %) and non-remission rate on day 33 was 4.5 % (range 0–23 %).

Conclusions

Lack of a centralized laboratory diagnosis or reference evaluation precludes any explanation of the heterogeneity of the clinical and laboratory values. The high percentage of deaths in remission is a major cause of failure.
Literatur
1.
Zurück zum Zitat Pui CH, Evans WE. Treatment of childhood acute lymphoblastic leukemia. N Engl J Med. 2006;354:166–78.PubMedCrossRef Pui CH, Evans WE. Treatment of childhood acute lymphoblastic leukemia. N Engl J Med. 2006;354:166–78.PubMedCrossRef
2.
Zurück zum Zitat Schrappe M, Nachman J, Hunger S, et al. Educational symposium on long-term results of large prospective clinical trials for childhood acute lymphoblastic leukemia (1985–2000). Editorial. Leukemia. 2010;24:253–4. Schrappe M, Nachman J, Hunger S, et al. Educational symposium on long-term results of large prospective clinical trials for childhood acute lymphoblastic leukemia (1985–2000). Editorial. Leukemia. 2010;24:253–4.
3.
Zurück zum Zitat Conter V, Aricò M, Basso G, et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia. 2010;24:255–64.PubMedCrossRef Conter V, Aricò M, Basso G, et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia. 2010;24:255–64.PubMedCrossRef
4.
Zurück zum Zitat Möricke A, Zimmermann M, Reiter A, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010;24:265–84.PubMedCrossRef Möricke A, Zimmermann M, Reiter A, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010;24:265–84.PubMedCrossRef
5.
Zurück zum Zitat Gaynon PS, Angiolillo AL, Carroll WL, et al. Long-term results of the children’s cancer group studies for childhood acute lymphoblastic leukemia 1983–2002: A Children’s Oncology Group Report. Leukemia. 2010;24:285–97.PubMedCrossRef Gaynon PS, Angiolillo AL, Carroll WL, et al. Long-term results of the children’s cancer group studies for childhood acute lymphoblastic leukemia 1983–2002: A Children’s Oncology Group Report. Leukemia. 2010;24:285–97.PubMedCrossRef
6.
Zurück zum Zitat Tallen G, Dworzak M, Gadner H, et al. Imperative of continual support by the European community for future advances in paediatric oncology in Europe: Meeting report of the EC-funded science-communication project direct ‘‘Overcoming Cancer with research’’. Memo. 2009;2:4–15. Tallen G, Dworzak M, Gadner H, et al. Imperative of continual support by the European community for future advances in paediatric oncology in Europe: Meeting report of the EC-funded science-communication project direct ‘‘Overcoming Cancer with research’’. Memo. 2009;2:4–15.
7.
Zurück zum Zitat Moericke A. Practical study execution on a national level. International Symposium on past successes and future challenges in pediatric oncology. Vienna, Austria, May 15–17, 2008. (Abstr # 8) Moericke A. Practical study execution on a national level. International Symposium on past successes and future challenges in pediatric oncology. Vienna, Austria, May 15–17, 2008. (Abstr # 8)
8.
Zurück zum Zitat Hiçsönmez G, Özsoylu S, Yetgin S, et al. Poor prognosis of childhood acute lymphoblastic leukaemia. Br Med J. 1983;286:1437 (Letter).CrossRef Hiçsönmez G, Özsoylu S, Yetgin S, et al. Poor prognosis of childhood acute lymphoblastic leukaemia. Br Med J. 1983;286:1437 (Letter).CrossRef
9.
Zurück zum Zitat Ulukutlu L, Sağlamer L, Yıldız İ. Results of chemotherapy in acute nonlymphoblastic leukemia in children. Farmaci Terapia. 1987;4:291–4. Ulukutlu L, Sağlamer L, Yıldız İ. Results of chemotherapy in acute nonlymphoblastic leukemia in children. Farmaci Terapia. 1987;4:291–4.
10.
Zurück zum Zitat Tatar M, Mollahaliloğlu S, Sahin B, et al. Turkey. Health system review. Health Syst Transit. 2011;13(6):1–186, xiii-xiv.PubMed Tatar M, Mollahaliloğlu S, Sahin B, et al. Turkey. Health system review. Health Syst Transit. 2011;13(6):1–186, xiii-xiv.PubMed
11.
Zurück zum Zitat Steinherz PG, Gaynon P, Miller DR, et al. Improved disease free survival of children with acute lymphoblastic leukemia at high risk for early response with the New York regimen—a new intensive therapy protocol: A report from the Children’s Cancer Study Group. J Clin Oncol. 1986;4:744–52.PubMed Steinherz PG, Gaynon P, Miller DR, et al. Improved disease free survival of children with acute lymphoblastic leukemia at high risk for early response with the New York regimen—a new intensive therapy protocol: A report from the Children’s Cancer Study Group. J Clin Oncol. 1986;4:744–52.PubMed
12.
Zurück zum Zitat Clavell LA, Gelber RXD, Cohen HJ, et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. New Engl J Med. 1986;315:657–63.PubMedCrossRef Clavell LA, Gelber RXD, Cohen HJ, et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. New Engl J Med. 1986;315:657–63.PubMedCrossRef
13.
Zurück zum Zitat Schrappe M, Beck J, Brandeis WE, et al. Die Behandlung der akuten lymphoblastischen Leukämie im Kindes- und Jugendalter: Ergebnisse der multizentrischen Therapiestudie ALL-BFM 81. Klin Pädiat. 1987;199:133–50.CrossRef Schrappe M, Beck J, Brandeis WE, et al. Die Behandlung der akuten lymphoblastischen Leukämie im Kindes- und Jugendalter: Ergebnisse der multizentrischen Therapiestudie ALL-BFM 81. Klin Pädiat. 1987;199:133–50.CrossRef
14.
Zurück zum Zitat Riehm H, Gadner H, Henze G, et al. Results and significance of six randomized trials in four consecutive ALL-BFM studies. Haematol Blood Transf. 1990;33:439–50. Riehm H, Gadner H, Henze G, et al. Results and significance of six randomized trials in four consecutive ALL-BFM studies. Haematol Blood Transf. 1990;33:439–50.
15.
Zurück zum Zitat Sağlamer L, Ulukutlu L, Yıldız İ. Improved prognosis in ALL with modified BFM protocols—preliminary results from Turkey. Haematol Blood Transf. 1994;36:347–51. Sağlamer L, Ulukutlu L, Yıldız İ. Improved prognosis in ALL with modified BFM protocols—preliminary results from Turkey. Haematol Blood Transf. 1994;36:347–51.
16.
Zurück zum Zitat İrken G, Ören H, Gülen H, et al. Treatment outcome of adolescents with acute lymphoblastic leukemia. Ann Hematol. 2002;81:641–5.PubMedCrossRef İrken G, Ören H, Gülen H, et al. Treatment outcome of adolescents with acute lymphoblastic leukemia. Ann Hematol. 2002;81:641–5.PubMedCrossRef
17.
Zurück zum Zitat Yüksel L, Yıldız İ, Celkan T, et al. Turkish experience with a modified non-B ALL-BFM 90 protocol. 2nd Biennial Hannover Symposium on childhood leukemia and lymphoma. Hannover, Germany, March 12–14, 2000. Abstract Booklet. Yüksel L, Yıldız İ, Celkan T, et al. Turkish experience with a modified non-B ALL-BFM 90 protocol. 2nd Biennial Hannover Symposium on childhood leukemia and lymphoma. Hannover, Germany, March 12–14, 2000. Abstract Booklet.
18.
Zurück zum Zitat Reiter A, Schrappe M, Ludwig WD, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood. 1994;84:3122–33.PubMed Reiter A, Schrappe M, Ludwig WD, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood. 1994;84:3122–33.PubMed
19.
Zurück zum Zitat Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy. Blood. 2000;95:3310–22.PubMed Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy. Blood. 2000;95:3310–22.PubMed
20.
Zurück zum Zitat Möricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: Treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008;111:4477–89.PubMedCrossRef Möricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: Treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008;111:4477–89.PubMedCrossRef
21.
Zurück zum Zitat Yüksel-Soycan L, Aydoğan G, Tanyeli A, et al. BFM-TR ALL 2000: First Turkish multicentric study in the treatment of pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer. 2006;47:426. (Abstract PC.013) Yüksel-Soycan L, Aydoğan G, Tanyeli A, et al. BFM-TR ALL 2000: First Turkish multicentric study in the treatment of pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer. 2006;47:426. (Abstract PC.013)
22.
Zurück zum Zitat Magrath I, Shanta V, Advani S, et al. Treatment of acute lymphoblastic leukaemia in countries with limited resources; lessons from use of a single protocol in India over a twenty year period. Eur J Cancer. 2005;41:1570–83.PubMedCrossRef Magrath I, Shanta V, Advani S, et al. Treatment of acute lymphoblastic leukaemia in countries with limited resources; lessons from use of a single protocol in India over a twenty year period. Eur J Cancer. 2005;41:1570–83.PubMedCrossRef
23.
Zurück zum Zitat Arora RS, Eden T, Pizer B. The problem of treatment abandonment in children from developing countries with cancer. Pediatr Blood Cancer. 2007;49:941–6.PubMedCrossRef Arora RS, Eden T, Pizer B. The problem of treatment abandonment in children from developing countries with cancer. Pediatr Blood Cancer. 2007;49:941–6.PubMedCrossRef
24.
Zurück zum Zitat Starý J, Mihál V, Smíšek P, et al. History of treatment and long-term outcome in children with acute lymphoblastic leukemia in the Czech Republic. Memo. 2001;4:1–7. Starý J, Mihál V, Smíšek P, et al. History of treatment and long-term outcome in children with acute lymphoblastic leukemia in the Czech Republic. Memo. 2001;4:1–7.
25.
Zurück zum Zitat Kutluk T, Yeşilipek MA. Turkish National Pediatric Cancer Registry 2002–2008. (Turkish Pediatric Oncology Group and Turkish Pediatric Hematology Society). Pediatr Blood Cancer. 2009;53:851. (Abstract PP.025) Kutluk T, Yeşilipek MA. Turkish National Pediatric Cancer Registry 2002–2008. (Turkish Pediatric Oncology Group and Turkish Pediatric Hematology Society). Pediatr Blood Cancer. 2009;53:851. (Abstract PP.025)
Metadaten
Titel
Significant heterogeneity between centers during early evaluation of the first Turkish multi-centric study in the treatment of childhood acute lymphoblastic leukemia
verfasst von
Lebriz Yüksel-Soycan
Publikationsdatum
01.12.2012
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2012
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-012-0043-y

Weitere Artikel der Ausgabe 4/2012

memo - Magazine of European Medical Oncology 4/2012 Zur Ausgabe